The present invention is directed to medical devices, systems, and methods, particularly for those which employ cold for treatment of pain in a patient. Embodiments of the invention include cryogenic cooling needles that can be advanced through skin or other tissues to inhibit neural transmission of pain signals. Other embodiments may inhibit muscle spasm induced pain. The cooling may be applied so that the pain-inhibiting remodeling relies on mechanisms other than ablation.
Therapeutic treatment of chronic or acute pain is among the most common reasons patients seek medical care. Chronic pain may be particularly disabling, and the cumulative economic impact of chronic pain is huge. A large portion of the population that is over the age of 65 may suffer from any of a variety of health issues which can predispose them to chronic or acute pain. An even greater portion of the nursing home population may suffer from chronic pain.
Current treatments for chronic pain may include pharmaceutical analgesics and electrical neurostimulation. While both these techniques may provide some level of relief, they can have significant drawbacks. For example, pharmaceuticals may have a wide range of systemic side effects, including gastrointestinal bleeding, interactions with other drugs, and the like. Opioid analgesics can be addictive, and may also of themselves be debilitating. The analgesic effects provided by pharmaceuticals may be relatively transient, making them cost-prohibitive for the aging population that suffers from chronic pain. While neurostimulators may be useful for specific applications, they generally involve surgical implantation, an expensive which carries its own risks, side effects, contraindications, on-going maintenance issues, and the like.
Neurolysis is a technique for treating pain in which a nerve is damaged so that it can no longer transmit pain signals. The use of neurotoxins (such as botulinum toxin or BOTOX®) for neurolysis has received some support. Unfortunately, significant volumes of toxins may be used on a regular basis for effective neurolysis, and such use of toxins can have significant disadvantages. Alternative neurolysis techniques may involve the use of thermal injury to the nerves via the application of radiofrequency (“RF”) energy to achieve ablation, cryoablation, or the like. While several of these alternative neurolysis approaches may avoid systemic effects and/or prevent damage, additional improvements to neurolysis techniques would be desirable.
In general, it would be advantageous to provide improved devices, systems, and methods for management of chronic and/or acute pain. Such improved techniques may avoid or decrease the systemic effects of toxin-based neurolysis and pharmaceutical approaches, while decreasing the invasiveness and/or collateral tissue damage of at least some known pain treatment techniques.
The present invention generally provides improved medical devices, systems, and methods for treatment of pain and other applications. Embodiments of the present invention may apply cooling with at least one probe inserted through an exposed skin surface (and/or other tissue overlying a nerve) of a patient. The cooling may remodel one or more target tissues so as to effect a desired change in composition of the target tissue and/or a change in its behavior. Exemplary embodiments will interfere with transmission of pain signals along sensory nerves. Alternative embodiments may interfere with the function of motor nerves, the function of contractile muscles, and/or some other tissue included in a contractile function chain so as to inhibit muscle contraction and thereby alleviate chronic or acute pain related to muscle activity. In some embodiments, other sources of pain such as components of the spine (optionally including herniated disks) may be treated.
In a first aspect, the invention provides a method for treating pain associated with a nerve of a patient. The nerve underlies a tissue. The method comprises manually manipulating a body of a treatment apparatus with a hand. The body supports a needle, and the body is manipulated so as to penetrate a sharpened distal end of the needle into the tissue to thermally couple the needle with the nerve. The body supports a cooling fluid source, and cooling fluid is transmitted from the source to the needle so that the fluid cools the needle and the needle cools the nerve sufficiently that pain is inhibited.
The cooling fluid may cool the needle to a needle temperature in a target temperature range. The target temperature range may be determined in response to a desired duration of pain inhibition. The needle temperature may, for example, be sufficiently warm to inhibit ablation of the nerve. The desired duration may optionally be permanent, and the needle temperature may be suitable to induce apoptosis of the nerve. Apoptosis-inducing treatments will not necessarily be permanent, as repair mechanisms may still limit the pain inhibiting duration. Nonetheless, apoptosis may enhance pain relief duration (for example, to provide pain relief lasting a plurality of months) and/or the duration of other effects of the cooling when compared to alternative treatment regimes. The desired duration may alternatively be less than permanent, for example, with the needle temperature being in a tissue stunning temperature range so that the nerve is capable of transmitting pain signals after the tissue warms. Optionally, the needle may be inserted in or adjacent to an epidural space near a spinal channel. By thermally coupling the needle to nerves within the spinal channel (and/or peripheral nerves branching from the spinal channel) cooling of the needle may be used to inhibit pain transmission into or via the spinal channel.
In the exemplary embodiment, the body comprises a self-contained, hand-held body so that no power, cooling fluid, or other material need be transmitted from a stationary structure along a flexible tether during treatment. At least a portion of the cooling may optionally be performed through an electrically insulating surface of the needle, with the needle often also having an electrically conductive surface. Measurement of the nerve may be provided by an electromyographic (“EMG”) system coupled to the electrically conductive surface of the needle. The needle will often be used to penetrate a skin surface of the patient overlying the nerve, and visible scar formation along the skin surface may be inhibited by limiting cooling along the needle proximally of the nerve. In some embodiments, a plurality of cooling cycles may be used to treat the nerve, with the probe being warmed or warm fluid being injected to speed thawing between the cooling cycles. In many embodiments, a needle may be detached from the body and another needle mounted in its place. The other needle is then used to cool tissue with cooling fluid from the cooling source. The body (and cooling fluid source) can be disposed of after treating only the one patient. Refilling of the cooling fluid source can be inhibited so as to prevent use of the system with another patient, for example, by configuring the cooling fluid path to release the lost gases through appropriately shaped vents rather than refill couplers or the like.
In another aspect, the invention provides a system for treating pain of a patient. The pain is associated with a nerve of the patient, and the nerve underlies a tissue. A system comprises a body having a handle and a needle that is supported by the handle. The needle has a proximal end adjacent the body and a distal end. The distal end is sharpened for penetrating distally into the tissue to thermally couple the needle with the nerve using manipulation of the handle. The cooling fluid source is mounted to the body and is supported by the handle. The cooling fluid source is coupled to the needle along a fluid path. A fluid flow control system is coupled to the fluid path so that the fluid cools the needle and the needle effects cooling of the nerve to inhibit the pain.
In another aspect, the invention provides a system for treating pain of a patient. The pain is associated with a nerve underlying a tissue of the patient. The system comprises a body having a handle and a needle that is supported by the handle. The needle has a proximal end adjacent the body and a distal end with a lumen extending between the proximal and distal ends. The distal end is sharpened for penetrating distally into the tissue so as to thermally couple the lumen with the nerve. The needle has a 16-gauge needle size or less. A cooling fluid source is coupled to the lumen of the needle by a fluid path, and a fluid flow control system coupled to the fluid path is configured to introduce cool fluid from the cooling fluid source, so that the vaporization of the fluid within the lumen effects cooling of the nerve to inhibit the pain.
The needle will often have a 22-gauge needle size or less, preferably having a 26-gauge needle size or less. Multiple needles may optionally be provided to enhance and/or widen a treatment volume, such as by providing two (or alternatively more than two) parallel and laterally offset needles. The fluid flow control system may comprise a length of silica tubing disposed along the fluid flow control path between the cooling fluid source and the lumen. Such tubing may have a small, very consistent inner diameter that helps meter the fluid flow, allowing the temperature to be effectively controlled by a simple pressure control valve disposed between the lumen and an exhaust.
In yet another aspect, the invention provides a method for treating pain associated with a component of a spine of a patient. The method comprises denervating at least a portion of the component, the at least a portion implicated in the pain. The component may comprise, for example, a disk of the patient, and the denervated portion may comprise an annulus fibrosus, a nucleus propulsus, and/or the like. Alternatively, herniation may be treated by modifying the collagen structure of the disk to strengthen the disk wall.
Very generally, the present invention provides improved medical devices, systems, and methods, most often for the treatment of pain. The invention will find application in a variety of medical treatments and diagnoses, particularly for pain management of patients suffering from chronic or acute pain. Many embodiments employ cooling to remodel one or more target tissues so as to effect a desired change in a composition of the target tissue, and/or a change in its behavior. For alleviation of pain, treatments may target nerve tissue so as to interfere with the generation or transmission of sensory nerve signals associated with the pain. Other embodiments may target motor nerve tissue, muscles, neuromuscular junctions, connective tissue, or the like, so as to alleviate pain associated with contraction of a muscle.
Chronic pain that may be treated using embodiments of the invention may include (but is not limited to) lower back pain, migraine headaches, and the like. Sources of chronic pain that may be alleviated at least in part via one or more aspects of the invention may be associated with herniated disks, muscle spasm or pinched nerves (in the back or anywhere in the rest of the body), foot pain (such as plantar fascitis, plantar fibroma, neuromas, neuritis, bursitis, ingrown toenails, and the like); pain associated with malignant tumors, and the like. Applications in lower back and extremity pain may include use for patients suffering from facet joint pain syndrome, pseudosciatica, intraspinous ligament injury, superior gluteal nerve entrapment, sacroiliac joint pain, cluneal neuralgia, peripheral neuropathy, and the like.
Acute pain that may be treated using embodiments of the invention include (but is not limited to) post-surgical pain (such as pain associated with thoracotomy or inguinal hernia repair), pain associated with procedures where an epidural block, spinal block, or other regional analgesia might otherwise be employed (such as during pregnancy, labor, and delivery to inhibit pain transmission via the sensory nerves without the use of drugs), and the like. Note that the ability to manage pain without (or with less) pharmaceutical agents may allow pain relief for an extended period of time and/or when drug interactions are of concern, for example, to allow pain reduction during early labor and decrease the potential for missing the window of time when an epidural can be administered.
Cooling times, temperatures, cooling fluid vaporization pressures, cooling fluid characteristics, cooling cycle times, and/or the like may be configured to provide a desired (often a selectable) efficacy time. Treatments at moderate temperatures (for example, at temperatures which only temporarily stun tissues but do not induce significant apoptosis or necrosis) may have only short term muscle contraction or pain signal transmission inhibiting effects. Other treatments may be longer lasting, optionally being permanent. Fibroblastic response-based efficacy may, in some embodiments, be self-limiting. Probe, applicator, and/or controller designs may allow treatments with efficacy that is less dependent on operator skill, thereby potentially allowing effective treatments to be applied by persons with more limited skill and/or training through automated temperature and time control. In some embodiments, no foreign bodies and/or material need be injected into and/or left behind after treatment. Other embodiments may combine, for example, cooling with application of materials such as bioactive agents, warmed saline, or the like, to limit injury and/or enhance remodeling efficacy. Some embodiments of treatments may combine cooling with pharmaceuticals, such as a neurotoxin or the like. In some embodiments, no tissues need be removed to achieve the desired therapeutic effect, although alternative embodiments may combine cooling with tissue removal.
In many embodiments, much or all of the treatment system may be included in a single hand-held apparatus. For example, a probe body in the form of a housing may contain a sealed cooling fluid cartridge having sufficient cooling fluid for treatment of a single patient. The housing may also contain a controller and battery, with the housing often being non-sterilizable and configured for disposal so as to limit capital investment and facilitate treatments in Third-World environments.
Target tissue temperatures for temporarily disabling nerves, muscles, and associated tissues so as to provide a “stun” effect may be fairly moderate, often being in a temperature range of from about −10° C. to −5° C. Such temperatures may not permanently disable the tissue structures, and may allow the tissues to return to normal function a relatively short time after warming. Using electromyographic systems, stimulation, or the like, a needle probe or other treatment device can be used to identify a target tissue, or the candidate target tissues may be cooled to a stunned temperature range to verify efficacy. In some embodiments, apoptosis may subsequently be induced using treatment temperatures from about −1° C. to about −15° C., or in some cases from about −1° C. to about −19° C. Apoptosis may optionally provide a permanent treatment that limits or avoids inflammation and mobilization of cellular repair. Colder temperatures may be applied to induce necrosis, which may be relatively long-lasting, and/or which may incite tissue healing response that eventually restores tissue function. Hence, the duration of treatment efficacy may be selected and controlled, with cooling temperatures, treatment times, and/or larger volume or selected patterns of target tissue determining the longevity of the treatment effects. Additional description of cryogenic cooling for treatment of cosmetic and other defects may be found in co-pending U.S. patent Ser. No. 11/295,204, filed on Dec. 5, 2005, and entitled “Subdermal Cryogenic Remodeling of Muscle, Nerves, Connective Tissue, and/or Adipose Tissue (Fat),” the full disclosure of which is incorporated herein by reference.
Referring now to
Extending distally from distal end 14 of housing 16 is a tissue-penetrating cryogenic cooling probe 26. Probe 26 is thermally coupled to a cooling fluid path extending from cooling fluid source 18, with the exemplary probe comprising a tubular body receiving at least a portion of the cooling fluid from the cooling fluid source therein. The exemplary probe 26 comprises a 30 g needle having a sharpened distal end that is axially sealed. Probe 26 may have an axial length between distal end 14 of housing 16 and the distal end of the needle of between about ½ mm and 5 cm, preferably having a length from about 1 cm to about 3 cm. Such needles may comprise a stainless steel tube with an inner diameter of about 0.006 inches and an outer diameter of about 0.012 inches, while alternative probes may comprise structures having outer diameters (or other lateral cross-sectional dimensions) from about 0.006 inches to about 0.100 inches. Generally, needle probe 26 will comprise a 16 g or smaller size needle, often comprising a 20 g needle or smaller, typically comprising a 25 g or smaller needle.
Addressing some of the components within housing 16, the exemplary cooling fluid supply 18 comprises a cartridge containing a liquid under pressure, with the liquid preferably having a boiling temperature of the less than 37° C. When the fluid is thermally coupled to the tissue-penetrating probe 26, and the probe is positioned within the patient so that an outer surface of the probe is adjacent to a target tissue, the heat from the target tissue evaporates at least a portion of the liquid and the enthalpy of vaporization cools the target tissue. A valve (not shown) may be disposed along the cooling fluid flow path between cartridge 18 and probe 26, or along the cooling fluid path after the probe so as to limit the temperature, time, rate of temperature change, or other cooling characteristics. The valve will often be powered electrically via power source 20, per the direction of processor 22, but may at least in part be manually powered. The exemplary power source 20 comprises a rechargeable or single-use battery.
The exemplary cooling fluid supply 18 comprises a single-use cartridge. Advantageously, the cartridge and cooling fluid therein may be stored and/or used at (or even above) room temperature. The cartridges may have a frangible seal or may be refillable, with the exemplary cartridge containing liquid N2O. A variety of alternative cooling fluids might also be used, with exemplary cooling fluids including fluorocarbon refrigerants and/or carbon dioxide. The quantity of cooling fluid contained by cartridge 18 will typically be sufficient to treat at least a significant region of a patient, but will often be less than sufficient to treat two or more patients. An exemplary liquid N2O cartridge might contain, for example, a quantity in a range from about 7 g to about 30 g of liquid.
Processor 22 will typically comprise a programmable electronic microprocessor embodying machine readable computer code or programming instructions for implementing one or more of the treatment methods described herein. The microprocessor will typically include or be coupled to a memory (such as a non-volatile memory, a flash memory, a read-only memory (“ROM”), a random access memory (“RAM”), or the like) storing the computer code and data to be used thereby, and/or a recording media (including a magnetic recording media such as a hard disk, a floppy disk, or the like; or an optical recording media such as a CD or DVD) may be provided. Suitable interface devices (such as digital-to-analog or analog-to-digital converters, or the like) and input/output devices (such as USB or serial I/O ports, wireless communication cards, graphical display cards, and the like) may also be provided. A wide variety of commercially available or specialized processor structures may be used in different embodiments, and suitable processors may make use of a wide variety of combinations of hardware and/or hardware/software combinations. For example, processor 22 may be integrated on a single processor board and may run a single program or may make use of a plurality of boards running a number of different program modules in a wide variety of alternative distributed data processing or code architectures.
Referring now to
The cooling fluid from valve 32 flows through a lumen 34 of a cooling fluid supply tube 36. Supply tube 36 is, at least in part, disposed within a lumen 38 of needle 26, with the supply tube extending distally from a proximal end 40 of the needle toward a distal end 42. The exemplary supply tube 36 comprises a fused silica tubular structure 36a having a polymer coating 36b (see
Though supply tubes 36 having outer jackets of polyimide (or other suitable polymer materials) may bend within the surrounding needle lumen 38, the supply tube should have sufficient strength to avoid collapsing or excessive blow back during injection of cooling fluid into the needle. Polyimide coatings may also provide durability during assembly and use, and the fused silica/polymer structures can handle pressures of up to 100 kpsi. The relatively thin tubing wall and small outer size of the preferred supply tubes allows adequate space for vaporization of the nitrous oxide or other cooling fluid within the annular space between the supply tube 36 and surrounding needle lumen 38. Inadequate space for vaporization might otherwise cause a buildup of liquid in that annular space and inconsistent temperatures. Exemplary structures for use as supply tube 36 may include the flexible fused silica capillary tubing sold commercially by Polymicro Technologies, LLC of Phoenix, Ariz. under model names TSP, TSG, and TSU, optionally including model numbers TSP 020090, TSP040105, and/or others.
Referring now to
During initiation of a cooling cycle, a large volume along the cooling fluid pathway between the exit from the supply tube and exit from the pressure relief valve 46 may cause excessive transients. In particular, a large volume in this area may result in initial temperatures that are significantly colder than a target and/or steady state temperature. This can be problematic, particularly when (for example) the target temperature is only slightly warmer than an undesirable effect inducing temperature, such as when remodeling through apoptosis or the like while seeking to inhibit necrosis. To limit such transients, the pressure relief valve 46 may be integrated into a housing 54 supporting needle 26, with the valve spring 52 being located outside the valve seat (and hence the pressure-control exit from pressure relief valve 46). Additionally, where needle 26 is included in a replaceable needle assembly 26A, pressure relief valve 46 is also located adjacent the interface between the needle assembly and probe handpiece housing 54. A detent 56 may be engaged by a spring supported catch to hold the needle assembly releasably in position, and the components of the needle assembly 26A (such as a brass or other metallic housing, a polyimide tubing 58, needle 26, and the like) may be affixed together using adhesive. Alternatively, as illustrated in
Additional aspects of the exemplary supply valves 32 can be understood with reference to
Referring now to
Very fine needles will typically be used to deliver to cooling at and/or below the surface of the skin. These needles can be damaged relatively easily if they strike a bone, or may otherwise be damaged or deformed before or during use. Fine needles will help inhibit damage to the skin during insertion, but may not be suitable for repeated insertion for treatment of numerous treatment sites or lesions of a particular patient, or for sequential treatment of a large area of the patient. Hence, the structures shown in
Referring now to
Pressure, cooling, or both may be applied 118 to the skin surface adjacent the needle insertion site before, during, and/or after insertion 120 and cryogenic cooling 122 of the needle and associated target tissue. The needle can then be retracted 124 from the target tissue. If the treatment is not complete 126 and the needle is not yet dull 128, pressure and/or cooling can be applied to the next needle insertion location site 118, and the additional target tissue treated. However, as small gauge needles may dull after being inserted only a few times into the skin, any needles that are dulled (or otherwise determined to be sufficiently used to warrant replacement, regardless of whether it is after a single insertion, 5 insertions, or the like) during the treatment may be replaced with a new needle 116 before the next application of pressure/cooling 118, needle insertion 120, and/or the like. Once the target tissues have been completely treated, or once the cooling supply cartridge included in the self-contained handpiece is depleted, the used handpiece and needles can be disposed of 130.
A variety of target treatment temperatures, times, and cycles may be applied to differing target tissues to as to achieve the desired remodeling. For example, (as more fully described in patent application Ser. No. 11/295,204, previously incorporated herein by reference) desired temperature ranges to temporarily and/or permanently disable muscle, as well as protect the skin and surrounding tissues, may be indicated by Table II as follows:
To provide tissue remodeling with a desired or selected efficacy duration, tissue treatment temperatures may be employed per Table III as follows:
There is a window of temperatures where apoptosis can be induced. An apoptotic effect may be temporary, long-term (lasting at least weeks, months, or years) or even permanent. While necrotic effects may be long term or even permanent, apoptosis may actually provide more long-lasting cosmetic benefits than necrosis. Apoptosis may exhibit a non-inflammatory cell death. Without inflammation, normal muscular healing processes may be inhibited. Following many muscular injuries (including many injuries involving necrosis), skeletal muscle satellite cells may be mobilized by inflammation. Without inflammation, such mobilization may be limited or avoided. Apoptotic cell death may reduce muscle mass and/or may interrupt the collagen and elastin connective chain. Temperature ranges that generate a mixture of these apoptosis and necrosis may also provide long-lasting or permanent benefits. For the reduction of adipose tissue, a permanent effect may be advantageous. Surprisingly, both apoptosis and necrosis may produce long-term or even permanent results in adipose tissues, since fat cells regenerate differently than muscle cells.
Referring now to
Referring now to
Referring now to
Referring now to
As can be understood with reference to
While exemplary embodiments have been described in some detail for clarity of understanding and by way of example, a number of modifications, changes, and adaptations may be implemented and/or will be obvious to those as skilled in the art. Hence, the scope of the present invention is limited solely by the independent claims.
The present application claims the benefit under 35 USC 119(e) of U.S. Provisional Application No. 60/987,992 filed Nov. 14, 2007; the full disclosure of which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2319542 | Hall | May 1943 | A |
2672032 | Towse | Mar 1964 | A |
3226492 | Steinberg | Dec 1965 | A |
3343544 | Dunn et al. | Sep 1967 | A |
3507283 | Thomas, Jr. | Apr 1970 | A |
3532094 | Stahl | Oct 1970 | A |
3664344 | Bryne | May 1972 | A |
3795245 | Allen, Jr. et al. | Mar 1974 | A |
3830239 | Stumpf et al. | Aug 1974 | A |
3886945 | Stumpf et al. | Jun 1975 | A |
3889681 | Waller et al. | Jun 1975 | A |
3951152 | Crandell et al. | Apr 1976 | A |
3993075 | Lisenbee et al. | Nov 1976 | A |
4140109 | Savic et al. | Feb 1979 | A |
4207897 | Lloyd et al. | Jun 1980 | A |
4306568 | Torre | Dec 1981 | A |
4376376 | Gregory | Mar 1983 | A |
4404862 | Harris, Sr. | Sep 1983 | A |
4524771 | McGregor et al. | Jun 1985 | A |
4758217 | Gueret | Jul 1988 | A |
4802475 | Weshahy | Feb 1989 | A |
4946460 | Merry et al. | Aug 1990 | A |
5200170 | McDow | Apr 1993 | A |
5334181 | Rubinsky et al. | Aug 1994 | A |
5571147 | Sluijter et al. | Nov 1996 | A |
5647868 | Chinn | Jul 1997 | A |
5755753 | Knowlton | May 1998 | A |
5814040 | Nelson et al. | Sep 1998 | A |
5899897 | Rabin et al. | May 1999 | A |
5916212 | Baust et al. | Jun 1999 | A |
5976505 | Henderson | Nov 1999 | A |
6003539 | Yoshihara | Dec 1999 | A |
6032675 | Rubinsky | Mar 2000 | A |
6039730 | Rabin et al. | Mar 2000 | A |
6041787 | Rubinsky | Mar 2000 | A |
6139545 | Utley et al. | Oct 2000 | A |
6141985 | Cluzeau et al. | Nov 2000 | A |
6182666 | Dobak, III | Feb 2001 | B1 |
6196839 | Ross | Mar 2001 | B1 |
6277099 | Strowe et al. | Aug 2001 | B1 |
6277116 | Utely et al. | Aug 2001 | B1 |
6371943 | Racz et al. | Apr 2002 | B1 |
6432102 | Joye et al. | Aug 2002 | B2 |
6494844 | Van Bladel et al. | Dec 2002 | B1 |
6503246 | Har-Shai et al. | Jan 2003 | B1 |
6506796 | Fesus et al. | Jan 2003 | B1 |
6546935 | Hooven | Apr 2003 | B2 |
6551309 | LePivert | Apr 2003 | B1 |
6562030 | Abboud et al. | May 2003 | B1 |
6648880 | Chauvet et al. | Nov 2003 | B2 |
6669688 | Svaasand et al. | Dec 2003 | B2 |
6672095 | Luo | Jan 2004 | B1 |
6706037 | Zvuloni et al. | Mar 2004 | B2 |
6723092 | Brown et al. | Apr 2004 | B2 |
6749624 | Knowlton | Jun 2004 | B2 |
6761715 | Carroll | Jul 2004 | B2 |
6764493 | Weber et al. | Jul 2004 | B1 |
6786902 | Rabin et al. | Sep 2004 | B1 |
6789545 | Littrup et al. | Sep 2004 | B2 |
6858025 | Maurice | Feb 2005 | B2 |
6905492 | Zvuloni et al. | Jun 2005 | B2 |
6960208 | Bourne et al. | Nov 2005 | B2 |
7081111 | Svaasand et al. | Jul 2006 | B2 |
7083612 | Littrup et al. | Aug 2006 | B2 |
7195616 | Diller et al. | Mar 2007 | B2 |
7217939 | Johansson et al. | May 2007 | B2 |
7250046 | Fallat | Jul 2007 | B1 |
7311672 | Van Bladel et al. | Dec 2007 | B2 |
7367341 | Anderson et al. | May 2008 | B2 |
7402140 | Spero et al. | Jul 2008 | B2 |
7422586 | Morris et al. | Sep 2008 | B2 |
7578819 | Bleich et al. | Aug 2009 | B2 |
20020013602 | Huttner | Jan 2002 | A1 |
20020045434 | Masoian et al. | Apr 2002 | A1 |
20020068929 | Zvuloni | Jun 2002 | A1 |
20020183731 | Holland et al. | Dec 2002 | A1 |
20020193778 | Alchas et al. | Dec 2002 | A1 |
20030036752 | Joye et al. | Feb 2003 | A1 |
20030109912 | Joye et al. | Jun 2003 | A1 |
20030181896 | Zvuloni et al. | Sep 2003 | A1 |
20040122482 | Tung et al. | Jun 2004 | A1 |
20040162551 | Brown et al. | Aug 2004 | A1 |
20040167505 | Joye et al. | Aug 2004 | A1 |
20040191229 | Link et al. | Sep 2004 | A1 |
20040204705 | Lafontaine | Oct 2004 | A1 |
20040210212 | Maurice | Oct 2004 | A1 |
20040215178 | Maurice | Oct 2004 | A1 |
20040215294 | Littrup et al. | Oct 2004 | A1 |
20040220648 | Carroll | Nov 2004 | A1 |
20040225276 | Burgess | Nov 2004 | A1 |
20040243116 | Joye et al. | Dec 2004 | A1 |
20050004563 | Racz et al. | Jan 2005 | A1 |
20050276759 | Roser et al. | Feb 2005 | A1 |
20050177147 | Vancelette et al. | Aug 2005 | A1 |
20050177148 | van der Walt et al. | Aug 2005 | A1 |
20050182394 | Spero et al. | Aug 2005 | A1 |
20050203505 | Megerman et al. | Sep 2005 | A1 |
20050203593 | Shanks | Sep 2005 | A1 |
20050209565 | Yuzhakov et al. | Sep 2005 | A1 |
20050209587 | Joye et al. | Sep 2005 | A1 |
20050228288 | Hurst | Oct 2005 | A1 |
20050251103 | Steffen et al. | Nov 2005 | A1 |
20050261753 | Littrup et al. | Nov 2005 | A1 |
20050283148 | Janssen et al. | Dec 2005 | A1 |
20060009712 | Van Bladel et al. | Jan 2006 | A1 |
20060015092 | Joye et al. | Jan 2006 | A1 |
20060069385 | Lafontaine et al. | Mar 2006 | A1 |
20060084962 | Joye et al. | Apr 2006 | A1 |
20060129142 | Reynolds | Jun 2006 | A1 |
20060189968 | Howlett et al. | Aug 2006 | A1 |
20060200117 | Hermans | Sep 2006 | A1 |
20060212028 | Joye et al. | Sep 2006 | A1 |
20060223052 | MacDonald et al. | Oct 2006 | A1 |
20060258951 | Bleich et al. | Nov 2006 | A1 |
20070060921 | Janssen et al. | Mar 2007 | A1 |
20070088217 | Babaev | Apr 2007 | A1 |
20070129714 | Elkins et al. | Jun 2007 | A1 |
20070156125 | DeLonzor | Jul 2007 | A1 |
20070161975 | Goulko | Jul 2007 | A1 |
20070167943 | Janssen et al. | Jul 2007 | A1 |
20070198071 | Ting et al. | Aug 2007 | A1 |
20070255362 | Levinson et al. | Nov 2007 | A1 |
20070270925 | Levinson | Nov 2007 | A1 |
20080077201 | Levinson et al. | Mar 2008 | A1 |
20080077202 | Levinson | Mar 2008 | A1 |
20080077211 | Levinson et al. | Mar 2008 | A1 |
20080154254 | Burger et al. | Jun 2008 | A1 |
20080183164 | Elkins et al. | Jul 2008 | A1 |
20080200910 | Burger et al. | Aug 2008 | A1 |
20080287839 | Rosen et al. | Nov 2008 | A1 |
20090018623 | Levinson et al. | Jan 2009 | A1 |
20090018624 | Levinson et al. | Jan 2009 | A1 |
20090018625 | Levinson et al. | Jan 2009 | A1 |
20090018626 | Levinson et al. | Jan 2009 | A1 |
20090018627 | Levinson et al. | Jan 2009 | A1 |
20090171334 | Elkins et al. | Jul 2009 | A1 |
Number | Date | Country |
---|---|---|
2 643 474 | Sep 2007 | CA |
0 043 447 | Jun 1981 | EP |
0 777123 | Jun 1997 | EP |
1 074 273 | Feb 2001 | EP |
1 377 327 | Sep 2007 | EP |
1 360 353 | Jul 1974 | GB |
1402632 | Aug 1975 | GB |
10-014656 | Jan 1989 | JP |
2006-130055 | May 2006 | JP |
WO 9749344 | Dec 1997 | WO |
WO 0197702 | Dec 2001 | WO |
WO 02092153 | Nov 2002 | WO |
WO 2004039440 | May 2004 | WO |
WO 2004045434 | Jun 2004 | WO |
WO 2004089460 | Oct 2004 | WO |
WO 2005000106 | Jan 2005 | WO |
WO 2005079321 | Sep 2005 | WO |
WO 2006012128 | Feb 2006 | WO |
WO 2006023348 | Mar 2006 | WO |
WO 2006125835 | Nov 2006 | WO |
WO 2007037326 | Apr 2007 | WO |
WO 2007089603 | Aug 2007 | WO |
WO 2007135629 | Nov 2007 | WO |
WO 2009026471 | Feb 2009 | WO |
Number | Date | Country | |
---|---|---|---|
20090248001 A1 | Oct 2009 | US |
Number | Date | Country | |
---|---|---|---|
60987992 | Nov 2007 | US |